Medlab Clinical Ltd (ASX:MDC), an Australian biotech using delivery platforms to enhance medicines is pleased to announce the execution of a Master Services Agreement with WEP Clinical Ltd for the exclusive development and delivery of Named Patient Programmes
Medlab Clinical Ltd
Medlab Clinical Limited (ASX:MDC) is pioneering the development and Commercialisation of a delivery platform, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab's pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. Patented lead drug candidate NanaBis(TM) has been developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis(TM) may be equally effective in non-cancer neuropathic pain. NanoCelle(R), the patented delivery platform is wholly owned by Medlab and developed in Medlab's owned OGTR Registered Laboratory. NanoCelle(R) is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia (Head Office), USA, and the UK.